Shree Dhootapapeshwar Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Shree Dhootapapeshwar Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $68.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Shree Dhootapapeshwar Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $68.1K Trade | TransData Nexus

Shree Dhootapapeshwar Limited

Indian Pharmaceutical Exporter · Ayurvedic & Herbal Products Specialist · $68.1K Total Trade · DGFT Verified

Shree Dhootapapeshwar Limited is an Indian pharmaceutical exporter with a total trade value of $68.1K across 2 products in 1 therapeutic categories. Based on 147 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Bhasma ($55.1K), Gutika ($13.0K), .

Shree Dhootapapeshwar Limited — Export Portfolio & Destination Treemap

Shree Dhootapapeshwar Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Shree Dhootapapeshwar Limited? — Company Overview & Market Position

Shree Dhootapapeshwar Limited (SDL) is a prominent Indian pharmaceutical company specializing in Ayurvedic formulations. Established in 1872 by Late Vaidyaraj Shri Krishnashastri Puranik, SDL holds the distinction of being the world's oldest Ayurvedic enterprise. The company is headquartered at 135, Nanubhai Desai Road, Khetwadi, Mumbai, Maharashtra 400004, India. As a public unlisted company, SDL is classified as a non-government entity limited by shares, with a Corporate Identification Number (CIN) of U24239MH1948PLC006626. The authorized capital stands at ₹15 million, with a paid-up capital of ₹14.979 million, reflecting a 99.86% paid-up ratio. The company employs between 200 to 500 individuals, indicating a medium-sized enterprise. For more information, their official website is sdlindia.com.

What Does Shree Dhootapapeshwar Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Bhasma$55.1K 2Gutika$13.0K

Product Portfolio — Top 2 by Export Value

Shree Dhootapapeshwar Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Bhasma	Ayurvedic & Herbal Products	$55.1K	123	13.3%	2
2	Gutika	Ayurvedic & Herbal Products	$13.0K	24	10.4%	3

Shree Dhootapapeshwar Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $68.1K. The top category is Ayurvedic & Herbal Products (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Shree Dhootapapeshwar Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

SDL operates manufacturing facilities in Mumbai and Panvel, Maharashtra. The Mumbai plant, located at the registered office address, is the primary manufacturing site. Additionally, SDL has a unit situated at Panvel, Maharashtra, indicating a strategic expansion to enhance production capabilities. Specific details regarding production capacities and specializations are not publicly disclosed.

3Key Leadership

The leadership team at SDL comprises several key individuals:

Ranjit Anand Puranik: Managing Director since October 1, 2009.

Suvarna Ranjit Puranik: Director since June 17, 2024.

Yashodhan Vishwanath Divekar: Director since October 31, 2020.

Nutan Rajan Patankar: Director since November 20, 2006.

Ramacharya Gudi: Whole-Time Director since February 18, 2025.

These leaders bring a wealth of experience and expertise to guide SDL's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Shree Dhootapapeshwar Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

SDL's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available sources. The company's focus on Ayurvedic formulations may pose challenges in obtaining regulatory approvals in these regions, which often have stringent requirements for traditional medicines. However, SDL's longstanding reputation and adherence to quality standards suggest potential avenues for market access. Further information would be required to assess their specific regulatory filings and approvals in these markets.

2Emerging Markets

SDL's export data indicates a modest presence in international markets, with a total export value of $68,000 USD across 147 shipments, primarily in the Ayurvedic & Herbal Products category. This suggests a nascent penetration into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The World Health Organization's prequalification program could facilitate SDL's entry into these markets by ensuring product quality and safety, thereby enhancing acceptance among local health authorities and consumers.

3Geographic Strategy

Shree Dhootapapeshwar Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding SDL's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. Given the challenges associated with marketing Ayurvedic products in the U.S., obtaining FDA approval would require comprehensive documentation and adherence to regulatory standards. Further research is necessary to determine SDL's current status and any potential pathways for market entry.

2WHO & EU GMP

There is no publicly available information confirming that SDL holds World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certifications. Acquiring these certifications would be instrumental in enhancing the company's credibility and facilitating access to international markets. Engaging in the certification process could open new avenues for SDL's products globally.

3CDSCO & Indian Regulatory

Shree Dhootapapeshwar Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the Ayurvedic pharmaceutical sector, SDL faces competition from both traditional Ayurvedic manufacturers and modern pharmaceutical companies expanding into herbal products. Key competitors include companies like Himalaya Drug Company, Dabur India Limited, and Patanjali Ayurved Limited. While SDL's longstanding heritage provides a competitive edge, its limited product diversification and export portfolio may impact its market share compared to these larger entities. A comprehensive market analysis is recommended to assess SDL's position relative to these competitors.

2Key Differentiators

SDL's unique strengths lie in its rich legacy of over 150 years in Ayurvedic medicine, specializing in classical and traditional formulations. The company's commitment to authenticity, standardization, safety, and efficacy distinguishes its products in the market. Additionally, SDL's adherence to Good Manufacturing Practice (GMP) and ISO 9001:2008 certifications underscores its dedication to quality.

3Strategic Position

Currently, SDL's strategic direction focuses on the production and export of Ayurvedic formulations, with an emphasis on traditional products like Bhasma and Gutika. The company's future outlook could benefit from diversifying its product portfolio and exploring new therapeutic areas to enhance its market presence. Engaging in research and development to create innovative products and obtaining international certifications could further strengthen SDL's position in the global market.

Buyer Due Diligence Brief — Evaluating Shree Dhootapapeshwar Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

SDL's track record in the Ayurvedic pharmaceutical industry is commendable, with a history spanning over 150 years. The company's export volume, though modest, demonstrates consistency in its international shipments. Reliability indicators, such as adherence to regulatory standards and quality certifications, further affirm SDL's reputation as a dependable supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

FDA Registration: Confirm that SDL's manufacturing facilities are registered with the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting SDL directly.

WHO-GMP Certification: Ensure that SDL holds certification from the World Health Organization's Good Manufacturing Practice program. This can be verified by reviewing WHO's official listings or by inquiring with SDL.

Frequently Asked Questions — Shree Dhootapapeshwar Limited

How many pharmaceutical products does Shree Dhootapapeshwar Limited export from India?

Shree Dhootapapeshwar Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Bhasma ($55.1K), Gutika ($13.0K). Total export value is $68.1K.

What is Shree Dhootapapeshwar Limited's total pharmaceutical export value?

Shree Dhootapapeshwar Limited's total pharmaceutical export value is $68.1K, based on 147 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Shree Dhootapapeshwar Limited cover?

Shree Dhootapapeshwar Limited exports across 1 therapeutic categories. The largest are Ayurvedic & Herbal Products (100.0%, 2 products).

Get Full Shree Dhootapapeshwar Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.